Association of changes in dyspnea, lung function, and physical activity by Indacaterol/Glycopyrronium combination in patients with COPD

Not Applicable

• Conditions: COPD

• Registration Number: JPRN-UMIN000024257
• Lead Sponsor: Yamaguchi University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-10-10
• Study Completion: 2021-10-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

1)Moderate-to-severe COPD exacerbation (requiring antibiotics, systemic steroids or hospitalization) within the 4 weeks before the screening 2)Requiring LABA and LAMA combination therapy 3)Requiring long-term oxygen therapy 4)Requiring short-acting beta2-agonista (SABA) relief use of more than 8 puffs/day 5)Concomitant pulmonary disease including asthma (FeNO<50ppb at baseline) 6)Any physical disorder that would prevent the patient from being able to complete the assessments 7)Long QT syndrome at screening, or a clinically significant electrocardiogram abnormality 8)History of closed angle glaucoma, and/or ischuria due to prostatic disease 9) There is a history of hypersensitivity to components of the Urutiburo

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary objective of this trial is to investigate the change in PA over a 12-week in response to QVA-149 (long-acting beta2 agonists (LABA)/long-acting muscarinic receptor antagonists (LAMA)) therapy in patients with COPD.